Search results
Showing 16 to 30 of 35 results for abiraterone
Evidence-based recommendations on darolutamide (Nubeqa) with androgen deprivation therapy and docetaxel for hormone-sensitive metastatic prostate cancer in adults.
Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)
Evidence-based recommendations on enzalutamide (Xtandi) for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.
data on the effectiveness of enzalutamide after previous treatment with abiraterone. Any explanatory notes(if applicable) The use of...
relapsed metastatic prostate cancer that has been previously treated with abiraterone, data should be collected on resource use and...
Degarelix for treating advanced hormone-dependent prostate cancer (TA404)
Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases.
Subscribe to NICE newsletters and alerts for the latest healthcare guidance, clinical updates, and evidence-based resources across health and social care.
In development Reference number: GID-TA11583 Expected publication date: TBC
Awaiting development Reference number: GID-TA11558 Expected publication date: TBC
Awaiting development Reference number: GID-TA11827 Expected publication date: TBC
Relugolix for treating hormone-sensitive prostate cancer (TA995)
Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.
Discontinued Reference number: GID-TA10465
In development Reference number: GID-TA10696 Expected publication date: TBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
In development Reference number: GID-TA10779 Expected publication date: TBC
Evidence-based recommendations on lutetium-177 vipivotide tetraxetan (Pluvicto) for treating prostate-specific membrane antigen-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments in adults.
Past technology appraisal appeals and decisions